| Name | Title | Contact Details |
|---|
E T Browne Drug Co Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Englewood Cliffs, NJ. To find more information about E T Browne Drug Co Inc, please visit www.etbrowne.com
Speciality Medical Billing is a Templeton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Project House is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vanguard Health Systems is an operator of hospitals and other medical facilities in five U.S. states: Arizona, Illinois, Massachusetts, Michigan, and Texas. The company's headquarters are located in Nashville, Tennessee. Vanguard owns twenty-six hospitals, including the ten Detroit Medical Center hospitals in Detroit, Michigan, five in San Antonio, Texas, four in the Chicago area, four in the Phoenix, Arizona area.
Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.